Safety, tolerability, and efficacy of high versus low-dose, short versus long-course daily primaquine for the radical cure of uncomplicated Plasmodium vivax malaria in children under 15 years of age: an open-label, non-inferiority, randomized controlled trial (CHILDPRIM)

Abstract Background Primaquine (PQ) is widely used to prevent Plasmodium vivax relapses. However, the most efficacious and safest dose is unknown, particularly in children. This trial assessed the safety, tolerability, and efficacy of two high-dose PQ regimens compared with standard of care (SoC) in...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Ana Luisa O. Pacheco, Aretha G. Omena, Djane C. Baía-da-Silva, Tyane A. P. Jardim, Debora C. B. Silva, Adriana P. B. Lopes, Laila R. A. Barbosa, Ingrid G. Souza, Renata F. Araujo, Luis O. S. Nogueira, Suianne C. N. Vale, Gisely C. Melo, Jady S. M. Cordeiro, Quique Bassat, Vanderson S. Sampaio, Valéria D. S. Lima, Flor E. Martinez-Espinosa, Maria Paula G. Mourão, Wuelton M. Monteiro, Maria Graças C. Alecrim, Jose Diego Brito-Sousa, Marcus V. G. Lacerda
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BMC 2025-12-01
Σειρά:	Malaria Journal
Θέματα:	Plasmodium vivax Malaria Children Paediatric Primaquine 8-Aminoquinolines
Διαθέσιμο Online:	https://doi.org/10.1186/s12936-025-05686-y
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!